Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2011-07-19
2011-07-19
Cheu, Jacob (Department: 1641)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007200, C436S518000
Reexamination Certificate
active
07981625
ABSTRACT:
Disclosed are methods for probing the immunogenic sugar moieties of prostate cancer cells. The methods detect a number of glyco-epitopes that are highly and differentially expressed among prostate cancers of various Gleason grades. The glyco-epitopes exist on the surfaces of prostate cells. The methods also comprise the detection of autoantibodies in prostate cancer subjects. The antibodies bound to a glyco-motif of N-glycans that is normally “cryptic.” This target is highly expressed in prostate cancers. Lectins and antibodies that detect these glyco-epitopes that expressed in prostate cancer tissues includeEuonymus europaeuslectin (EEL);Psophocarpus TetragonolobusLectin-I (PTL-I);Griffonia SimplicifoliaLectin-I-A4 (GSL-I-A4);Griffonia SimplicifoliaLectin-I-B4 (GSL-I-B4);Sambucus nigraI agglutinin (SNA-I;Phaseolus vulgaris-L (PHA-L;Galanthus nivalisagglutinin (GNA);Narcissus pseudonarcissusagglutinin (NPA);Artocarpus integrifoliaagglutinin (Jacalin); and mAb TM10 (IgM).
REFERENCES:
patent: 4725557 (1988-02-01), Miyauchi et al.
patent: 5432260 (1995-07-01), Stahl
patent: 5766853 (1998-06-01), Parma et al.
patent: 2003/0228637 (2003-12-01), Wang
patent: 2004/0033546 (2004-02-01), Wang
patent: 2008/0071148 (2008-03-01), Bosques et al.
patent: 2002064556 (2002-08-01), None
patent: 2003016464 (2003-02-01), None
Denong Wang, et al., “Glycan arrays lead to the discovery of autoimmunogenic activity of SARS-CoV,” Physiol. Genomics, May 25, 2004, vol. 18, 245-248.
Jean-Frederic Sanchez, et al., “Biochemical and Structural Analysis of Helix pomatia Agglutinin,” J. of Biolog. Chemistry, Jul. 21, 2006, vol. 281, No. 29, 20171-20180.
Gregory T. Carroll, et al., “Photons to illuminate the universe of sugar diversity through bioarrays,” Glycoconj J, 2008, 25:5-10.
Stephen L. Hart, et al., “Cell Binding and Internalization by Filamentous Phage Displaying a Cyclic Arg-Gly-Asp-containing Peptide,” Journal of Biological Chemistry, Apr. 29, 1994, vol. 269, No. 17, 12468-12474.
Istvan Botos, et al., “Structures of the Complexes of a Potent Anti-HIV Protein Cyanovirin-N and High Mannose Oligosaccharides,” Journal of Biological Chemistry, Sep. 13, 2002, vol. 277, No. 37, 34336-34342.
Thomas E. Newsom-Davis, et al., “Enhanced Immune Recognition of Cryptic Glycan Markers in Human Tumors,” Cancer Res, Mar. 1, 2009; vol. 65, No. 5, 2018-2025.
Alvin Y. Liu, et al., “Characterization of Prostate Cell Types by CD Cell Surface Molecules,” Am. J. Pathology, Jan. 2002, vol. 160, No. 1, 37-43.
D. M. Peehl, “Primary cell cultures as models of prostate cancer development,” Endocrine-Related Cancer, 2005, vol. 12, 19-47.
Julius S. Horoszewicz, et al., “LNCaP Model of Human Prostatic Carcinoma,” Cancer Research, Apr. 1983, vol. 43, 1809-1818.
Hiroaki Tateno, et al., “A novel strategy for mammalian cell surface glycome profiling using lectin microarray,” Glycobiology, Aug. 10, 2007, vol. 17, No. 10, 1138-1146.
Ola Blixt, et al., “Printed covalent glycan array for ligand profiling of diverse glycan binding proteins,” PNAS, Dec. 7, 2004, vol. 101, No. 49, 17033-17038.
Denong Wang, et al., “Carbohydrate microarrays for the recognition of cross-reactive molecular markers of microbes and host cells,” Nature Biotechnology, Mar. 2002, Vo. 20, 275-281.
LecChip Brochure, Moritex Corporation, 2008, 6 pp.
Herzenberg Leonard A.
Herzenberg Leonore A.
Peehl Donna M.
Wang Denong
Aston David J.
Cheu Jacob
Peters Verny LLP
The Board of Trustees of the Leland Stanford Junior University
LandOfFree
Prostate cancer glycan markers and autoantibody signatures does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Prostate cancer glycan markers and autoantibody signatures, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prostate cancer glycan markers and autoantibody signatures will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2668775